Trastuzumab works by binding to the extracellular domain of the HER2 receptor, which is a member of the epidermal growth factor receptor (EGFR) family. This binding prevents the receptor from dimerizing and activating downstream signaling pathways that promote cell growth and survival. Additionally, trastuzumab recruits immune cells to the cancer cells, enhancing the bodyâs immune response against the tumor.
